Immunis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS to TREATMENT for SARCOPENIC OBESITY
- Conditions
- SarcopeniaObesity and Obesity-related Medical Conditions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Immunis, Inc.
- Registration Number
- NCT06784297
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
Phase 2
Recruiting
- Conditions
- Muscle PerformanceSarcopenic Obesity
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Immunis, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT06600581
- Locations
- 🇺🇸
National Institute of Clinical Research (NICR), Pomona, California, United States
🇺🇸Johnson Country Clinical Trials (JCCT), Lenexa, Kansas, United States
🇺🇸Tekton Research, Wichita, Kansas, United States
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Immunis, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05211986
- Locations
- 🇺🇸
University of California, Irvine - Alpha Stem Cell Clinic, Orange, California, United States
© Copyright 2025. All Rights Reserved by MedPath